These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34779140)

  • 1. Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
    Toorop MMA; Chen Q; Kruip MJHA; van der Meer FJM; Nierman MC; Faber L; Goede L; Cannegieter SC; Lijfering WM
    J Thromb Haemost; 2022 Feb; 20(2):339-352. PubMed ID: 34779140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
    Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN.
    van Miert JHA; Kooistra HAM; Veeger NJGM; Westerterp A; Piersma-Wichers M; Meijer K
    Thromb Res; 2020 Jun; 190():69-75. PubMed ID: 32315869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study.
    Toorop MMA; Chen Q; Tichelaar VYIG; Cannegieter SC; Lijfering WM
    Eur Heart J; 2021 Oct; 42(40):4126-4137. PubMed ID: 34269375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin.
    Pundi KN; Perino AC; Fan J; Schmitt S; Kothari M; Szummer K; Askari M; Heidenreich PA; Turakhia MP
    J Am Heart Assoc; 2021 Dec; 10(23):e020904. PubMed ID: 34779243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation.
    Vinding NE; Butt JH; Olesen JB; Xian Y; Kristensen SL; Rørth R; Bonde AN; Gundlund A; Yafasova A; Weeke PE; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    J Am Heart Assoc; 2022 Mar; 11(6):e024402. PubMed ID: 35229642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Previous INR Control during VKA Therapy on Subsequent DOAC Adherence and Persistence, in Patients Switched from VKA to DOAC.
    Elling T; Hak E; Bos JH; Tichelaar VYIG; Veeger NJGM; Meijer K
    Thromb Haemost; 2024 Aug; 124(8):778-790. PubMed ID: 37673103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.
    Manzoor BS; Walton SM; Sharp LK; Galanter WL; Lee TA; Nutescu EA
    J Thromb Thrombolysis; 2017 Nov; 44(4):435-441. PubMed ID: 29027097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.
    Zielinski GD; van Rein N; Teichert M; Klok FA; Rosendaal FR; van der Meer FJM; Huisman MV; Cannegieter SC; Lijfering WM
    Res Pract Thromb Haemost; 2020 Jan; 4(1):141-153. PubMed ID: 31989096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
    Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
    Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral anticoagulant switching in patients with atrial fibrillation: a scoping review.
    Adelakun AR; Turgeon RD; De Vera MA; McGrail K; Loewen PS
    BMJ Open; 2023 Apr; 13(4):e071907. PubMed ID: 37185198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
    Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease.
    Douros A; Cui Y; Platt RW; Filion KB; Sebastiani G; Renoux C
    Br J Clin Pharmacol; 2022 Mar; 88(3):994-1009. PubMed ID: 34409636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions.
    Kirchmayer U; Narduzzi S; Mayer F; Tuccori M; Leoni O; Belleudi V; Di Martino M; Lallo A; Addis A; Davoli M
    Recenti Prog Med; 2019 Apr; 110(4):195-202. PubMed ID: 31066365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation.
    Sakamoto Y; Okubo S; Nito C; Suda S; Matsumoto N; Abe A; Aoki J; Shimoyama T; Takayama Y; Suzuki K; Mishina M; Kimura K
    Eur J Neurol; 2017 Nov; 24(11):1399-1406. PubMed ID: 28799181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage.
    Tsivgoulis G; Lioutas VA; Varelas P; Katsanos AH; Goyal N; Mikulik R; Barlinn K; Krogias C; Sharma VK; Vadikolias K; Dardiotis E; Karapanayiotides T; Pappa A; Zompola C; Triantafyllou S; Kargiotis O; Ioakeimidis M; Giannopoulos S; Kerro A; Tsantes A; Mehta C; Jones M; Schroeder C; Norton C; Bonakis A; Chang J; Alexandrov AW; Mitsias P; Alexandrov AV
    Neurology; 2017 Sep; 89(11):1142-1151. PubMed ID: 28814457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.